Acinetobacter baumanniirelated mortality in intensive care units in Colombia;Mortalidad por Acinetobacter baumannii en unidades de cuidados intensivos en Colombia

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 30, Issue 4, 2011, Pages 287-294

  Lemos, Elkin V ^a   De La Hoz Restrepo, Fernando ^a   Alvis, Nelson ^b   Quevedo, Elkin ^c   Cañon, Oscar ^d   León, Yazmin ^e  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b UNIVERSIDAD DE CARTAGENA   (Colombia)

^c Fundación Para El Desarrollo y Apoyo en Salud Internacional FUDASAI   (Colombia)

^d UNIVERSIDAD SANTO TOMÁS   (Colombia)

^e Clinical Laboratory   (Colombia)

Author keywords

Acinetobacter baumannii; Anti bacterial agents; Colombia; Drug resistance; Hospital mortality; Intensive care units; Microbial

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIUM; DRUG RESISTANCE; HEALTH RISK; MORTALITY; MULTIVARIATE ANALYSIS; RISK FACTOR;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLOMBIA; COMPARATIVE STUDY; CROSS INFECTION; DRUG EFFECT; FEMALE; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLOMBIA; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INPATIENTS; INTENSIVE CARE UNITS; LOGISTIC MODELS; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; STATISTICS AS TOPIC; YOUNG ADULT;

COLOMBIA;

ACINETOBACTER; ACINETOBACTER BAUMANNII; BACTERIA (MICROORGANISMS);

EID: 82955200043     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. World Health Organization. Containing Antimicrobial Resistant. Review of the Literature and Report of a WHO Workshop on the Development of a Global Strategy for the Containment of Antimicrobial Resistance. Geneva: World Healh Organization; 1999.
2. Acar JF. Consequences of bacterial resistance to antibiotics in medical practice. Clin Infect Dis. 1997;24 (1 supl):S17-8.
3. Zavascki AP, Carvalhaes CG, Picao RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and A. baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther. 2010;8(1):71-93.
4. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY. Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis. 2001;32(2 supl):S104-13. (Pubitemid 32424265)
5. Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Nanas S, Markaki V, et al. Carbapenem-resistant versus carbapenemsusceptible A. baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. 2010;38(3):173-180.
6. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999;27(5):887-92. (Pubitemid 29266004)
7. Brenner P, Otaíza F, Bustamante R. Nosocomial infections outbreaks in Chile 1985-2002. Am J Infect Control. 2004;32(3):E49.
8. Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, et al. Clinical and economic impact of multidrug resistance in nosocomial A. baumannii bacteremia. Infect Control Hosp Epidemiol. 2007;28(6):713-9.
9. The Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol. 2002;23(2):106-8.
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Wayne: Clinical Laboratory Standards Institute; 2006. (16th Informational Supplement M100-S16).
11. Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. 1995;108(6):1655-62.
12. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53(282):457-81.
13. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17: 857-72. (Pubitemid 28185165)
14. Wilson EB. Probable Inference, the Law of Succession, and Statistical Inference. J Am Stat Assoc. 1927;22:209-12.
15. Scerpella EG, Wanger AR, Armitige L, Anderlini P, Ericsson CD. Nosocomial outbreak caused by a multiresistant clone of A. baumannii: results of the case-control and molecular epidemiologic investigations. Infect Control Hosp Epidemiol. 1995;16(2):92-7.
16. Weingarten CM, Rybak MJ, Jahns BE, Stevenson JG, Brown WJ, Levine DP. Evaluation of A. baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital. Pharmacotherapy. 1999;19(9):1080-5. (Pubitemid 29413647)
17. Shorr AF. Review of studies on the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med. 2009;37(4):1463-9.
18. Kollef MH. Epidemiology and risk factors for nosocomial pneumonia. Emphasis on prevention. Clin Chest Med. 1999;20(3):653-70. (Pubitemid 29466251)
19. Jang TN, Lee SH, Huang CH, Lee CL, Chen WY. Risk factors and impact of nosocomial A. baumannii bloodstream infections in the adult intensive care unit: a case-control study. J Hosp Infect. 2009;73(2):143-50.
20. Playford EG, Craig JC, Iredell JR. Carbapenemresistant A. baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect. 2007; 65:204.